Clinical TrialsCYB004 approaching a key inflection point, with completed enrollment in the Phase 2a trial in generalized anxiety disorder positioning the upcoming readout as a catalyst that could reshape investor perception of DMT programs.
Financial StabilityThe recent announcement of a US$500 million convertible debenture facility—with US$50 million now funded—provides additional capital flexibility and extends runway beyond 2026.
PartnershipsCybin has expanded its partnership with Thermo Fisher Scientific to include U.S.-based manufacturing of both CYB003 drug substance and capsules, supporting Phase 3 supply and future commercial scale-up.